The Expression Of AMACR, P63, HCK And PSAP In Prostate Cancer And Their Diagnostic Values

Objective: To investigate the expression of α -2-methylacyl - CoA- racemase (AMACR, P504S) , p63 , HCK and PSAP in prostate carcinoma tissues of 45 cases and their adjacent benign prostatic tissue , to discuss the clinicopathologic significance of above-mentioned methods in the diagnosis of the disease. Methods: The expression of AMACR , p63, HCK and PSAP in 45 cases of prostate carcinoma and 45 cases of adjacent benign prostate lesions were examined using immunohistochemical method. The association of the AMACR, p63,HCK and PSAP expression in prostate carcinoma tissues with the differentiation and clinical staging was evaluated. Results: The positive rates of AMACR , p63 , HCK and PSAP were 91.1% (41 /45), 88.9% (40 /45), 93.3% (42 /45) and 95.6%(44 /45) respectively in prostate carcinoma tissues, and the positive rate of AMACR were 22. 2% (10 /45), and the positive rate of p63 and HCK are both 0% in benign prostatic hyperplasia tissue and PSAP positive rate is 100% in benign prostatic hyperplasia tissue . There were significant differences of these values between prostate carcinoma and benign prostatic hyperplasia (P< 0. 01) except PSAP statistically. The high level expression of AMACR and low level expression of p63 and HCK were not correlated with differentiation degree of prostate carcinoma ( P > 0. 05). Conclusions : Overexpression of AMACR and underexpression of p63 and HCK may be the preliminary incident of the formation of prostate carcinoma, which may induce carcinoma into occurrence and progression. Thus these may be early diagnostic parameters , PSAP can be used as a differerntial diagnosis parameter.